Treatment principles for peritoneal surface malignancies

Marcello Deraco, Shigeki Kusamura, Carlo Corbellini, Marcello Guaglio, Cosimo Pavig Lianiti, Dario Baratti

Research output: Contribution to journalReview article

Abstract

A paradigm shift has recently occurred in the clinical management of peritoneal surface malignancies (PSM). Once regarded as end-stage disseminated conditions only to be palliated, PSM are now increasingly recognized as localregional disease entities amenable to potentially curative therapies. Better knowledge of the natural history and patterns of disease-progression has evolved into a novel treatment approach combining aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy, to treat the microscopic residual disease. Such a complex comprehensive treatment has reportedly resulted in a survival improvement over historical controls, and it is gaining an increasing acceptance as standard of care for selected patients with peritoneal metastases from gastrointestinal and gynecological tumor and rare primary peritoneal malignancies. This article addresses the rational bases supporting the comprehensive treatment of PSM. The biology and patho-physiology of peritoneal tumor dissemination, with their implication on surgical and local-regional management are reviewed. The cytoreductive surgical procedures and intraperitoneal chemotherapy administration techniques are described, together with the theoretical principles from which have originated. The main controversial issues in the operative management of PSM are discussed, focusing on the technical variants adopted in our institution. The most recent literature data on both patient selection and appropriate indications for combined treatment are presented. Additionally, a brief overview of treatment results and long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the different PSM is provided.

Original languageEnglish
Pages (from-to)124-145
Number of pages22
JournalMinerva Chirurgica
Volume71
Issue number2
Publication statusPublished - Apr 1 2016

Fingerprint

Neoplasms
Therapeutics
Drug Therapy
Standard of Care
Natural History
Patient Selection
Disease Progression
Neoplasm Metastasis
Survival

Keywords

  • Cytoreduction surgical procedures
  • Drug therapy
  • Neoplasm metastasis
  • Peritoneum

ASJC Scopus subject areas

  • Surgery

Cite this

Deraco, M., Kusamura, S., Corbellini, C., Guaglio, M., Pavig Lianiti, C., & Baratti, D. (2016). Treatment principles for peritoneal surface malignancies. Minerva Chirurgica, 71(2), 124-145.

Treatment principles for peritoneal surface malignancies. / Deraco, Marcello; Kusamura, Shigeki; Corbellini, Carlo; Guaglio, Marcello; Pavig Lianiti, Cosimo; Baratti, Dario.

In: Minerva Chirurgica, Vol. 71, No. 2, 01.04.2016, p. 124-145.

Research output: Contribution to journalReview article

Deraco, M, Kusamura, S, Corbellini, C, Guaglio, M, Pavig Lianiti, C & Baratti, D 2016, 'Treatment principles for peritoneal surface malignancies', Minerva Chirurgica, vol. 71, no. 2, pp. 124-145.
Deraco M, Kusamura S, Corbellini C, Guaglio M, Pavig Lianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chirurgica. 2016 Apr 1;71(2):124-145.
Deraco, Marcello ; Kusamura, Shigeki ; Corbellini, Carlo ; Guaglio, Marcello ; Pavig Lianiti, Cosimo ; Baratti, Dario. / Treatment principles for peritoneal surface malignancies. In: Minerva Chirurgica. 2016 ; Vol. 71, No. 2. pp. 124-145.
@article{51918086561b41ef9ceb623d875f7a6c,
title = "Treatment principles for peritoneal surface malignancies",
abstract = "A paradigm shift has recently occurred in the clinical management of peritoneal surface malignancies (PSM). Once regarded as end-stage disseminated conditions only to be palliated, PSM are now increasingly recognized as localregional disease entities amenable to potentially curative therapies. Better knowledge of the natural history and patterns of disease-progression has evolved into a novel treatment approach combining aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy, to treat the microscopic residual disease. Such a complex comprehensive treatment has reportedly resulted in a survival improvement over historical controls, and it is gaining an increasing acceptance as standard of care for selected patients with peritoneal metastases from gastrointestinal and gynecological tumor and rare primary peritoneal malignancies. This article addresses the rational bases supporting the comprehensive treatment of PSM. The biology and patho-physiology of peritoneal tumor dissemination, with their implication on surgical and local-regional management are reviewed. The cytoreductive surgical procedures and intraperitoneal chemotherapy administration techniques are described, together with the theoretical principles from which have originated. The main controversial issues in the operative management of PSM are discussed, focusing on the technical variants adopted in our institution. The most recent literature data on both patient selection and appropriate indications for combined treatment are presented. Additionally, a brief overview of treatment results and long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the different PSM is provided.",
keywords = "Cytoreduction surgical procedures, Drug therapy, Neoplasm metastasis, Peritoneum",
author = "Marcello Deraco and Shigeki Kusamura and Carlo Corbellini and Marcello Guaglio and {Pavig Lianiti}, Cosimo and Dario Baratti",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "71",
pages = "124--145",
journal = "Minerva Chirurgica",
issn = "0026-4733",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Treatment principles for peritoneal surface malignancies

AU - Deraco, Marcello

AU - Kusamura, Shigeki

AU - Corbellini, Carlo

AU - Guaglio, Marcello

AU - Pavig Lianiti, Cosimo

AU - Baratti, Dario

PY - 2016/4/1

Y1 - 2016/4/1

N2 - A paradigm shift has recently occurred in the clinical management of peritoneal surface malignancies (PSM). Once regarded as end-stage disseminated conditions only to be palliated, PSM are now increasingly recognized as localregional disease entities amenable to potentially curative therapies. Better knowledge of the natural history and patterns of disease-progression has evolved into a novel treatment approach combining aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy, to treat the microscopic residual disease. Such a complex comprehensive treatment has reportedly resulted in a survival improvement over historical controls, and it is gaining an increasing acceptance as standard of care for selected patients with peritoneal metastases from gastrointestinal and gynecological tumor and rare primary peritoneal malignancies. This article addresses the rational bases supporting the comprehensive treatment of PSM. The biology and patho-physiology of peritoneal tumor dissemination, with their implication on surgical and local-regional management are reviewed. The cytoreductive surgical procedures and intraperitoneal chemotherapy administration techniques are described, together with the theoretical principles from which have originated. The main controversial issues in the operative management of PSM are discussed, focusing on the technical variants adopted in our institution. The most recent literature data on both patient selection and appropriate indications for combined treatment are presented. Additionally, a brief overview of treatment results and long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the different PSM is provided.

AB - A paradigm shift has recently occurred in the clinical management of peritoneal surface malignancies (PSM). Once regarded as end-stage disseminated conditions only to be palliated, PSM are now increasingly recognized as localregional disease entities amenable to potentially curative therapies. Better knowledge of the natural history and patterns of disease-progression has evolved into a novel treatment approach combining aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy, to treat the microscopic residual disease. Such a complex comprehensive treatment has reportedly resulted in a survival improvement over historical controls, and it is gaining an increasing acceptance as standard of care for selected patients with peritoneal metastases from gastrointestinal and gynecological tumor and rare primary peritoneal malignancies. This article addresses the rational bases supporting the comprehensive treatment of PSM. The biology and patho-physiology of peritoneal tumor dissemination, with their implication on surgical and local-regional management are reviewed. The cytoreductive surgical procedures and intraperitoneal chemotherapy administration techniques are described, together with the theoretical principles from which have originated. The main controversial issues in the operative management of PSM are discussed, focusing on the technical variants adopted in our institution. The most recent literature data on both patient selection and appropriate indications for combined treatment are presented. Additionally, a brief overview of treatment results and long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the different PSM is provided.

KW - Cytoreduction surgical procedures

KW - Drug therapy

KW - Neoplasm metastasis

KW - Peritoneum

UR - http://www.scopus.com/inward/record.url?scp=84971457412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971457412&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84971457412

VL - 71

SP - 124

EP - 145

JO - Minerva Chirurgica

JF - Minerva Chirurgica

SN - 0026-4733

IS - 2

ER -